Abstract:Study objective Both high fat diet and aldosterone challenge can cause significant renal damage, either as a primary cause or as co‐morbidities with other diseases (e.g. cardiovascular diseases and diabetes). Angiotensin‐converting‐enzyme inhibitor (ACEi) and mineralocorticoid receptor inhibitor (MRi; e.g. spinronolactone and eplerenone) are commonly used in these patients. However their mortality is still high and such treatments are not suitable for all patients. Thus, a new therapeutic approach is warranted for renal damages. Herein, we hypothesize that lipocalin‐2 plays a detrimental role in both dietary and aldosterone‐induced renal injuries, and thus could be a novel drug target for therapeutic development. Methods Wild‐type (WT), lipocalin‐2 knockout (LKO) and lipocalin‐2 tissue specific knockout in adipose tissue (ADN‐Cre) mice were subjected to eight weeks of high fat diet treatment or to nephrectomy followed by four weeks of aldosterone/nephrectomy/1% saline treatment (ANS). MRi (either spinronolactone or eplerenone) was administered in ANS‐treated groups to compare its efficacy versus lipocalin‐2 deficiency mice in terms of anti‐hypertensive effect, renal damages and fibrosis, and small resistance artery stiffness and tone. Adipose tissue of all mice was also collected for further analysis. Results Compared to MRi‐treated wildtype mice, LKO and ADN‐Cre mice showed a better protection against ANS‐induced renal damages, as evidenced by: (1) attenuation of tissue fibrosis, (2) decreased infiltration of macrophages, (3) reduced levels of molecular injury markers, such as kidney injury marker (KIM)‐1, monocyte chemoattractant protein (MCP)‐1, transforming growth factor (TFG)‐β and collagen I. In addition, LKO and ADN‐Cre mice treated with high fat diet showed significant protection from renal damages and reduced adipose tissue fibrosis when compared to controls. As regards small resistance artery stiffness and compliance, ADN‐Cre mice were protected against ANS and high fat diet challenge. Conclusion Lipocalin‐2 is involved in the development of the metabolic‐renal syndrome. Targeting its expression and/or signalling pathways could be a novel therapeutic approach to combat these medical complications. Support or Funding Information This work was supported by the grants from Hong Kong Research Grant Council [General Research (17121714, HKU 763312 and HKU 780613M), Collaborative Research Fund (C705514G)] and an educational grant from Les Laboratories Servier (RS100503).

Mfsd2a mediated lysolipid transport is important for renal recovery after acute kidney injury

Macrophage Migration Inhibitory Factor Promotes Renal Injury Induced by Ischemic Reperfusion

Mitofusin-2 Mediated Mitochondrial Ca2+ Uptake 1/2 Induced Liver Injury in Rat Remote Ischemic Perconditioning Liver Transplantation and Alpha Mouse Liver-12 Hypoxia Cell Line Models.

Renal Tubular Epithelial Cells RIPK3 Promote AKI Progressing to CKD

USP13 Targets MCL-1 to Protect Mitochondria-Attenuating AKI

Loss of long-chain acyl-CoA dehydrogenase protects against acute kidney injury

Inhibition of ACSF2 protects against renal ischemia/reperfusion injury via mediating mitophagy in proximal tubular cells

The regulation of LPCAT3 by miR-124-3p.1 in acute kidney injury suppresses cell proliferation by disrupting phospholipid metabolism

Deletion of Antigen-Presenting Cells in Lipopolysaccharide-Induced Acute Kidney Injury (AKI) Affects the Exacerbation and Repair in AKI

Lasmiditan restores mitochondrial quality control mechanisms and accelerates renal recovery after ischemia-reperfusion injury

Low Molecular Weight Fucoidan Against Renal Ischemia-Reperfusion Injury Via Inhibition of the Mapk Signaling Pathway

Aldehyde Dehydrogenase 2 Ameliorates LPS-Induced Acute Kidney Injury Through Detoxification of 4-HNE and Suppression of the MAPK Pathway

TSC1 deletion in fibroblasts alleviates lipopolysaccharide-induced acute kidney injury

Role of Lipocalin‐2 in Dietary and Aldosterone‐induced Renal Damages

5-Hydroxytryptamine 1F Receptor Agonist Lasmiditan Differentially Regulates Successful Repair and Failed Repair Genes in a Mouse Model of Acute Kidney Injury

Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

#3581 ACSS2-INDUCED FATTY ACID SYNTHESIS PROMOTES NLRP3 INFLAMMASOME AND PYROPTOSIS OF RENAL TUBULAR CELLS IN SEPSIS-INDUCED ACUTE KIDNEY INJURY

Exploring the role and therapeutic potential of lipid metabolism in acute kidney injury

Deficiency in SIRP-α cytoplasmic recruitment confers protection from acute kidney injury

ACSF2 and Lysine Lactylation Contribute to Renal Tubule Injury in Diabetes

DsbA‐L deletion attenuates LPS‐induced acute kidney injury by modulating macrophage polarization